Comprehensive stability-indicating method development of Avanafil Phosphodiesterase type 5 inhibitor using advanced Quality-by-Design approach

Abstract Avanafil (AV) is the phosphodiesterase (PDE) type 5 inhibitor drug used in erectile dysfunction, having pyrrolidine, pyrimidine, carboxamide, and chlorine as functional groups which can easily break by environmental changes and cause toxicity. Henceforth, in detail, HPLC stability study wit...

Full description

Bibliographic Details
Main Authors: Mital Patel, Charmy Kothari
Format: Article
Language:English
Published: SpringerOpen 2020-07-01
Series:Journal of Analytical Science and Technology
Subjects:
Online Access:http://link.springer.com/article/10.1186/s40543-020-00228-4
id doaj-caaea25740364f6b966b0a5c9a775305
record_format Article
spelling doaj-caaea25740364f6b966b0a5c9a7753052020-11-25T03:36:42ZengSpringerOpenJournal of Analytical Science and Technology2093-33712020-07-0111111410.1186/s40543-020-00228-4Comprehensive stability-indicating method development of Avanafil Phosphodiesterase type 5 inhibitor using advanced Quality-by-Design approachMital Patel0Charmy Kothari1Department of Pharmaceutical Analysis, Institute of Pharmacy, Nirma UniversityDepartment of Pharmaceutical Analysis, Institute of Pharmacy, Nirma UniversityAbstract Avanafil (AV) is the phosphodiesterase (PDE) type 5 inhibitor drug used in erectile dysfunction, having pyrrolidine, pyrimidine, carboxamide, and chlorine as functional groups which can easily break by environmental changes and cause toxicity. Henceforth, in detail, HPLC stability study with the Quality-by-Design (QbD) approach is presented which leads to recommended storage conditions. The stability of AV was analyzed in hydrolysis, photolysis, and thermal and oxidative conditions. The application of the QbD approach during the stability method development comprises steps as screening and optimization. Quality target product profile (QTPP) was defined, and critical quality attributes (CQAs) were assigned to meet the QTPP requirements. Primary parameters obtained from the Ishikawa diagram were studied via Placket–Burman, and four critical factors were optimized through the central composite design (CCD). The finalized method includes mobile phase [10 mM ammonium acetate, pH 4.5 adjusted by acetic acid:ACN (60:40, v/v)] at 0.9-mL/min flow rate and 239-nm wavelength. A control strategy was set up to ensure that the method repeatedly meets the acceptance criteria. Overall, 16 degradation product peaks of AV in all conditions (solid and solution state) were identified with optimized method and evaluated by HPLC-PDA study. A comprehensive systemic optimization of AV stability study is stated for the first time, which reveals that AV is prone to degrade in sunlight, moisture, and temperature. Global regulators and manufacturers should take care of the packaging, handling, and labeling of AV. A fully validated LC–MS compatible stability method can be successfully applied to monitor AV stability from its formulation which can be wisely extrapolated to assess the AV from biological samples. Graphical abstracthttp://link.springer.com/article/10.1186/s40543-020-00228-4Avanafil (AV)Degradation productsStorage conditionQuality by Design (QbD)Chemical stabilityErectile dysfunction
collection DOAJ
language English
format Article
sources DOAJ
author Mital Patel
Charmy Kothari
spellingShingle Mital Patel
Charmy Kothari
Comprehensive stability-indicating method development of Avanafil Phosphodiesterase type 5 inhibitor using advanced Quality-by-Design approach
Journal of Analytical Science and Technology
Avanafil (AV)
Degradation products
Storage condition
Quality by Design (QbD)
Chemical stability
Erectile dysfunction
author_facet Mital Patel
Charmy Kothari
author_sort Mital Patel
title Comprehensive stability-indicating method development of Avanafil Phosphodiesterase type 5 inhibitor using advanced Quality-by-Design approach
title_short Comprehensive stability-indicating method development of Avanafil Phosphodiesterase type 5 inhibitor using advanced Quality-by-Design approach
title_full Comprehensive stability-indicating method development of Avanafil Phosphodiesterase type 5 inhibitor using advanced Quality-by-Design approach
title_fullStr Comprehensive stability-indicating method development of Avanafil Phosphodiesterase type 5 inhibitor using advanced Quality-by-Design approach
title_full_unstemmed Comprehensive stability-indicating method development of Avanafil Phosphodiesterase type 5 inhibitor using advanced Quality-by-Design approach
title_sort comprehensive stability-indicating method development of avanafil phosphodiesterase type 5 inhibitor using advanced quality-by-design approach
publisher SpringerOpen
series Journal of Analytical Science and Technology
issn 2093-3371
publishDate 2020-07-01
description Abstract Avanafil (AV) is the phosphodiesterase (PDE) type 5 inhibitor drug used in erectile dysfunction, having pyrrolidine, pyrimidine, carboxamide, and chlorine as functional groups which can easily break by environmental changes and cause toxicity. Henceforth, in detail, HPLC stability study with the Quality-by-Design (QbD) approach is presented which leads to recommended storage conditions. The stability of AV was analyzed in hydrolysis, photolysis, and thermal and oxidative conditions. The application of the QbD approach during the stability method development comprises steps as screening and optimization. Quality target product profile (QTPP) was defined, and critical quality attributes (CQAs) were assigned to meet the QTPP requirements. Primary parameters obtained from the Ishikawa diagram were studied via Placket–Burman, and four critical factors were optimized through the central composite design (CCD). The finalized method includes mobile phase [10 mM ammonium acetate, pH 4.5 adjusted by acetic acid:ACN (60:40, v/v)] at 0.9-mL/min flow rate and 239-nm wavelength. A control strategy was set up to ensure that the method repeatedly meets the acceptance criteria. Overall, 16 degradation product peaks of AV in all conditions (solid and solution state) were identified with optimized method and evaluated by HPLC-PDA study. A comprehensive systemic optimization of AV stability study is stated for the first time, which reveals that AV is prone to degrade in sunlight, moisture, and temperature. Global regulators and manufacturers should take care of the packaging, handling, and labeling of AV. A fully validated LC–MS compatible stability method can be successfully applied to monitor AV stability from its formulation which can be wisely extrapolated to assess the AV from biological samples. Graphical abstract
topic Avanafil (AV)
Degradation products
Storage condition
Quality by Design (QbD)
Chemical stability
Erectile dysfunction
url http://link.springer.com/article/10.1186/s40543-020-00228-4
work_keys_str_mv AT mitalpatel comprehensivestabilityindicatingmethoddevelopmentofavanafilphosphodiesterasetype5inhibitorusingadvancedqualitybydesignapproach
AT charmykothari comprehensivestabilityindicatingmethoddevelopmentofavanafilphosphodiesterasetype5inhibitorusingadvancedqualitybydesignapproach
_version_ 1724548529074995200